On April 23, 2025, Ascentage Pharma Group International announced it will present data from two clinical studies, including key assets Lisaftoclax and Alrizomadlin, at the 2025 ASCO Annual Meeting. This event is deemed significant as it highlights the company’s ongoing development efforts.